Formulation and optimization of porous osmotic pump-based controlled release system of oxybutynin.
The aim of the current study was to design a porous osmotic pump-based drug delivery system for controlled release of oxybutynin. The porous osmotic pump contains pore-forming water-soluble additives in the coating membrane, which after coming in contact with water, dissolve, resulting in an in situ formation of a microporous structure. The dosage regimen of oxybutynin is one 5-mg tablet 2 to 3 times a day. The plasma half-life ranges from approximately 2 to 3 hours. Hence, oxybutynin was chosen as a model drug with an aim to develop a controlled release system for a period of 24 hours. Linear and reproducible release similar to that of Ditropan XL was achieved for optimized formulation (f2 >50) independent of hydrodynamic conditions. The effect of different formulation variables, namely, ratio of drug to osmogent, membrane weight gain, and level of pore former on the in vitro release was studied. Cellulose acetate (CA) was used as the semipermeable membrane. It was found that drug release rate increased with the amount of osmogent because of the increased water uptake, and hence increased driving force for drug release. Oxybutynin release was inversely proportional to the membrane weight gain; however, directly related to the level of pore former, sorbitol, in the membrane. This system was found to deliver oxybutynin at a zero-order rate for 20 hours. The effect of pH on drug release was also studied. The optimized formulations were subjected to stability studies as per International Conference on Harmonisation (ICH) guidelines and formulations were stable after a 3 month study.
Kanagale
Pritam
P
Department of Novel Drug Delivery Systems, Zydus Research Centre, Sarkhej-Bavla N. H. No. 8A, Moraiya, Ahmedabad-382210, Gujarat, India.
Lohray
Braj Bhushan
BB
Misra
Ambikanandan
A
Davadra
Prakash
P
Kini
Rajesh
R
D002626:Chemistry, Pharmaceutical; D003692:Delayed-Action Preparations; D004355:Drug Stability; D005079:Excipients; D006863:Hydrogen-Ion Concentration; D008333:Mandelic Acids / Q000008:administration & dosage* / Q000737:chemistry; D008855:Microscopy, Electron, Scanning; D009997:Osmotic Pressure; D016062:Porosity; D012995:Solubility; D013607:Tablets
D003692:Delayed-Action Preparations; D005079:Excipients; D008333:Mandelic Acids; D013607:Tablets; C005419:oxybutynin